Table 2 Logistic regression analysis results

From: Estimating single nucleotide polymorphism associations using pedigree data: applications to breast cancer

  

AOCS controls vs all female cases

AOCS controls vs one selected female case per family

SNP

Pedigrees

Affected/unaffected

RAF a

OR (95% CI) b

P -value

Affected/unaffected

RAF a

OR (95% CI) b

P -value

rs2981582

1577

1460/892

0.398

1.44 (1.26–1.65)

1.46 × 10−7

837/892

0.398

1.36 (1.18–1.58)

0.00003

rs1975930

1515

1504/813

0.106

0.75 (0.60–0.94)

0.01115

812/813

0.106

0.74 (0.58–0.95)

0.01788

rs10941679

1485

719/873

0.258

1.16 (0.99–1.36)

0.07327

601/873

0.258

1.19 (1.01–1.41)

0.03899

rs3803662

1558

1461/872

0.274

1.30 (1.13–1.50)

0.00024

845/872

0.274

1.31 (1.12–1.52)

0.00069

rs2046210

1563

1471/874

0.348

1.14 (1.00–1.31)

0.05218

846/874

0.348

1.17 (1.01–1.35)

0.03836

rs614367

1607

1571/891

0.158

1.19 (1.01–1.40)

0.04325

877/891

0.158

1.20 (1.00–1.44)

0.05003

rs10509168

1608

1563/892

0.474

0.80 (0.71–0.92)

0.00124

846/892

0.474

0.80 (0.69–0.92)

0.00205

rs1292011

1433

823/812

0.432

0.95 (0.82–1.10)

0.50408

574/812

0.432

0.95 (0.81–1.11)

0.50687

rs13387042

1551

1452/863

0.483

1.41 (1.24–1.61)

2.61 × 10−7

790/863

0.483

1.38 (1.20–1.60)

0.00001

rs13281615

1561

1422/874

0.402

1.19 (1.04–1.35)

0.01090

838/874

0.402

1.16 (1.01–1.34)

0.03900

rs865686

1511

1426/812

0.393

0.90 (0.78–1.03)

0.13578

775/812

0.393

0.86 (0.73–1.00)

0.04650

rs11249433

1565

1474/875

0.413

1.11 (0.97–1.27)

0.11657

847/875

0.413

1.08 (0.94–1.25)

0.29256

rs2823093

1511

1489/813

0.252

0.97 (0.84–1.14)

0.74598

792/813

0.252

0.92 (0.78–1.09)

0.35286

rs3817198

1562

1463/873

0.324

1.10 (0.96–1.26)

0.18494

846/873

0.324

0.98 (0.84–1.14)

0.81915

rs889312

1560

1462/871

0.280

1.13 (0.98–1.31)

0.08430

840/871

0.280

1.14 (0.97–1.33)

0.10425

rs1011970

1608

1573/892

0.161

1.12 (0.95–1.32)

0.18912

860/892

0.161

1.08 (0.89–1.30)

0.43456

rs17468277

1564

1468/875

0.141

0.79 (0.65–0.96)

0.01540

853/875

0.141

0.78 (0.63–0.97)

0.02331

rs999737

1528

1492/831

0.746

1.16 (0.99–1.35)

0.05823

853/831

0.746

1.16 (0.99–1.37)

0.07231

rs2380205

1580

898/891

0.408

1.15 (1.00–1.32)

0.05295

636/891

0.408

1.09 (0.95–1.26)

0.22967

rs4973768

1558

1439/873

0.455

1.22 (1.07–1.39)

0.00289

814/873

0.455

1.22 (1.06–1.41)

0.00507

rs6504950

1563

1468/875

0.302

0.92 (0.80–1.06)

0.26037

858/875

0.302

0.96 (0.82–1.11)

0.56381

rs2363956

1507

1388/813

0.502

1.06 (0.92–1.21)

0.42933

775/813

0.502

1.06 (0.92–1.23)

0.43906

rs8170

1512

1496/813

0.191

1.02 (0.86–1.21)

0.78295

806/813

0.191

1.04 (0.87–1.26)

0.64778

rs12662670

1514

1500/813

0.065

1.60 (1.25–2.04)

0.00016

799/813

0.065

1.67 (1.28–2.17)

0.00015

  1. Abbreviations: AOCS=Australian Ovarian Cancer Study; CI=confidence interval; OR=odds ratio; RAF=risk allele frequency; SNP, single-nucleotide polymorphism.
  2. aRAF is the observed risk allele frequency in unaffected individuals.
  3. bPer-allele OR is reported such that the effect allele is the same as those from the population-based studies (Supplementary Table 1).
Back to article page